This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Arcutis Biotherapeutics, a Westlake Village-based company developing drugs for immune dermatological conditions, plans to raise $150 million through a public offering of additional shares of common stock. Arcutis announced the pricing of those shares on Aug. 2, at $20 per share. Shares of Arcutis closed at $19.50 that day and then shot up 17% on Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Interlink Electronics, an Irvine-based sensor manufacturer with its research and development hub in Camarillo, announced Sept. 23 that it plans to expand its European presence with a new engineering team in Scotland. The new team will start with five engineers and will be located near the University of Strathclyde in Glasgow. To support the group, Read More →
Shares of Westlake Village-based Arcutis Biotherapeutics dropped by as much as 5% during the trading day July 1, after the biotech company terminated phase 2 trials for a potential treatment. Arcutis, a biotech company focused on creating dermatology treatments, has announced July that it had terminated phase 2a and 2b trials for evaluating ARQ-252, a Read More →
Westlake Village-based Arcutis Biotherapeutics suffered a net loss in the first quarter of fiscal year 2021, but continues to hold a strong financial position with $446.5 million in assets. According to earnings released May 4, Arcutis lost $36 million in the first quarter, or 76 cents per share, compared to a loss of $28 million, Read More →